FDA approves nivolumab plus cabozantinib for advanced renal cell carcinoma
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

ASCO: Pembrolizumab Ups DFS in High-Risk Resected Clear-Cell RCC
FRIDAY, June 4, 2021 -- For patients with fully resected intermediate-high-risk or high-risk clear-cell renal cell carcinoma (ccRCC), adjuvant therapy with pembrolizumab yields a significant and clinically meaningful improvement in disease-free... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2021 Category: Pharmaceuticals Source Type: news

Dana-Farber researchers present key studies at ASCO annual meeting
(Dana-Farber Cancer Institute) Dana-Farber Cancer Institute researchers are presenting at the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO). Toni K. Choueiri, MD, will present results from the randomized, double-blind, phase III KEYNOTE-564 trial evaluating pembrolizumab versus placebo after surgery in patients with renal cell carcinoma during ASCO's Plenary Session. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 20, 2021 Category: Cancer & Oncology Source Type: news

Occult Brain Mets Detected in Patients With Advanced Renal Cancer
MONDAY, May 3, 2021 -- Occult brain metastasis is identified in about 4 percent of patients with metastatic renal cell carcinoma (mRCC), according to a study published in the April issue of the Journal of the National Comprehensive Cancer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 3, 2021 Category: Pharmaceuticals Source Type: news

Metastatic renal-cell carcinoma treated with first-line monotherapy: considerable burden, high unmet needs
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 30, 2021 Category: Drugs & Pharmacology Source Type: news

FDA D.I.S.C.O. Burst Edition: FDA approval of Fotivda (tivozanib) for adult patients with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies
Listen to a soundcast of the March 10, 2021 FDA approval of Fotivda (tivozanib) for adult patients with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 9, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Obesity Tied to Increased Mortality Overall in Patients With Cancer
Risk for death lower for patients with lung cancer, renal cell carcinoma, melanoma with versus without obesity (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 30, 2021 Category: Cancer & Oncology Tags: Dermatology, Gastroenterology, Gynecology, Internal Medicine, Nephrology, Oncology, Pathology, Pulmonology, Radiology, Journal, Source Type: news

High BMI Tied to Better Overall Survival in Immune Checkpoint Inhibitor-Treated Metastatic RCC High BMI Tied to Better Overall Survival in Immune Checkpoint Inhibitor-Treated Metastatic RCC
In patients with metastatic renal cell carcinoma treated with PD-1/PD-L1-based immune checkpoint inhibitors (ICIs), higher body mass index was associated with improved overall survival in a database study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 15, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FOTIVDA (tivozanib), FDA Approved for Treatment of Relapsed/Refractory Advanced Renal Cell Carcinoma, Available at Biologics by McKesson
CARY, N.C., March 12, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by AVEO Oncology as a specialty pharmacy provider for FOTIVDA® (tivozanib) for the treatment of adult patients with relapsed or refractory advanced renal ... (Source: McKesson News)
Source: McKesson News - March 12, 2021 Category: Information Technology Source Type: news

Aveo finally earns approval for kidney cancer drug
More than 14 years after Boston-based Aveo Oncology licensed an experimental cancer drug from a Japanese biotech, the company announced Wednesday that the drug has earned approval by the U.S. Food and Drug Administration to treat kidney cancer, ending a long and tumultuous journey. The pill has the generic name of tivozanib, and will be marketed under the brand name, Fotivda, for use by patients with relapsed or refractory advanced renal cell carcinoma who have tried at least two other drugs previously. The… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 10, 2021 Category: Pharmaceuticals Authors: Don Seiffert Source Type: news

Aveo finally earns approval for kidney cancer drug
More than 14 years after Boston-based Aveo Oncology licensed an experimental cancer drug from a Japanese biotech, the company announced Wednesday that the drug has earned approval by the U.S. Food and Drug Administration to treat kidney cancer, ending a long and tumultuous journey. The pill has the generic name of tivozanib, and will be marketed under the brand name, Fotivda, for use by patients with relapsed or refractory advanced renal cell carcinoma who have tried at least two other drugs previously. The… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 10, 2021 Category: Biotechnology Authors: Don Seiffert Source Type: news

FDA approves tivozanib for relapsed or refractory advanced renal cell carcinoma
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 10, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Fotivda (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma
BOSTON--(BUSINESS WIRE) March 10, 2021 -- AVEO Oncology (Nasdaq: AVEO) today announced that the U.S. Food and Drug Administration (FDA) has approved Fotivda (tivozanib) for the treatment of adults with relapsed or refractory advanced renal cell... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 10, 2021 Category: Drugs & Pharmacology Source Type: news

New hope for advanced kidney cancer patients
Renal cell carcinoma, the most common form of kidney cancer, can quickly spread through the body and if diagnosed at a late stage it is usually inoperable, with patients given only a year to live. (Source: the Mail online | Health)
Source: the Mail online | Health - March 6, 2021 Category: Consumer Health News Source Type: news

Nivolumab Plus Cabozantinib Tops Sunitinib for Renal Cell Carcinoma
WEDNESDAY, March 3, 2021 -- For patients with previously untreated advanced renal cell carcinoma, nivolumab plus cabozantinib has significant benefits over sunitinib with respect to progression-free and overall survival, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 3, 2021 Category: Pharmaceuticals Source Type: news

Oncotarget: Identification intermediate-risk subgroups in metastatic clear-cell renal cell carcinoma
(Impact Journals LLC) " Elevated PLT count seems to identify a subgroup of patients with poor outcome in the IMDC intermediate-risk population with ccRCC " (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 1, 2021 Category: Cancer & Oncology Source Type: news

Cabozantinib may be cost effective in advanced renal cell carcinoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2021 Category: Drugs & Pharmacology Source Type: news

FDA D.I.S.C.O. Burst Edition: Enhertu (fam-trastuzumab deruxtecan-nxki ) and combination of Opdivo (nivolumab) and Cabometyx (cabozantinib)
Enhertu (fam-trastuzumab deruxtecan-nxki) for locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma and received a prior trastuzumab-based regimen. Combination of Opdivo (nivolumab) + Cabometyx (cabozantinib) as first-line treatment for advanced renal cell carcinoma (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 25, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

CT-guided renal ablation is safe for treating cancer in obese patients
CT-guided renal ablation is a safe and effective alternative to nephrectom...Read more on AuntMinnie.comRelated Reading: AI could help radiologists better detect kidney cancer Cryoablation comparable to surgery for kidney cancer Do more CT scans lead to more kidney surgeries? SPECT/CT can solve renal cell carcinoma diagnosis conundrum (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 24, 2021 Category: Radiology Source Type: news

Lenvatinib Plus Pembrolizumab Tops Sunitinib in Advanced RCC
FRIDAY, Feb. 19, 2021 -- For first-line treatment of advanced renal cell carcinoma, progression-free and overall survival are significantly longer with lenvatinib plus pembrolizumab versus sunitinib, according to a study published online Feb. 13 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 19, 2021 Category: Pharmaceuticals Source Type: news

Combo Shows'Impressive' Survival Results in First-Line RCC Combo Shows'Impressive' Survival Results in First-Line RCC
The combination of lenvatinib and pembrolizumab outperformed sunitinib as first-line therapy for advanced clear-cell renal cell carcinoma (RCC) in the CLEAR trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 18, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Cabozantinib Prolongs PFS in Papillary Renal Cell Carcinoma
WEDNESDAY, Feb. 17, 2021 -- For adults with papillary renal cell carcinoma (PRCC), the dual vascular endothelial growth factor (VEGF)-MET (hepatocyte growth factor receptor) inhibitor cabozantinib improves progression-free survival (PFS), according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 17, 2021 Category: Pharmaceuticals Source Type: news

Cabozantinib Could Be New Standard for Papillary RCC Cabozantinib Could Be New Standard for Papillary RCC
Cabozantinib outperforms the current standard of care for renal cell carcinoma (RCC), according to results from the Southwest Oncology Group 1500 trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 17, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Which Patients With Kidney Cancer Are Likely to Respond to ICI? Which Patients With Kidney Cancer Are Likely to Respond to ICI?
Several factors in patients with clear cell renal cell carcinoma are associated with a diminished response to immune checkpoint inhibition (ICI).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 5, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA approves nivolumab plus cabozantinib for advanced renal cell carcinoma
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 22, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

U.S. Food and Drug Administration Approves Opdivo (nivolumab) in Combination with Cabometyx (cabozantinib) as First-line Treatment for Patients with Advanced Renal Cell Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE) January 22, 2021-- Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 240 mg (injection for intravenous use) every two weeks or 480 mg every four weeks in combination with Cabometyx... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 22, 2021 Category: Drugs & Pharmacology Source Type: news

Researchers uncover potentially promising therapeutic combination for renal cell carcinoma
(Beth Israel Deaconess Medical Center) Investigators have demonstrated that ACE2 expression is a good prognostic factor in RCC, that loss of ACE2 mediates resistance to classical treatments, and that in preclinical models, treatment with a drug that is downstream of ACE2 can improve tumor responses in RCC and significantly prolong survival. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 20, 2021 Category: Cancer & Oncology Source Type: news

Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase-deficient renal cancer
Understanding the mechanisms of the Warburg shift to aerobic glycolysis is critical to defining the metabolic basis of cancer. Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is an aggressive cancer characterized by biallelic inactivation of the gene encoding the Krebs cycle enzyme fumarate hydratase, an early shift to aerobic glycolysis, and rapid metastasis. We observed impairment of the mitochondrial respiratory chain in tumors from patients with HLRCC. Biochemical and transcriptomic analyses revealed that respiratory chain dysfunction in the tumors was due to loss of expression of mitochondrial DNA (mtDNA)&n...
Source: Signal Transduction Knowledge Environment - January 5, 2021 Category: Science Authors: Crooks, D. R., Maio, N., Lang, M., Ricketts, C. J., Vocke, C. D., Gurram, S., Turan, S., Kim, Y.-Y., Cawthon, G. M., Sohelian, F., De Val, N., Pfeiffer, R. M., Jailwala, P., Tandon, M., Tran, B., Fan, T. W.- M., Lane, A. N., Ried, T., Wangsa, D., Malayeri Tags: STKE Research Articles Source Type: news

Peninsula biotech Calithera cuts a third of jobs after kidney cancer trial flop
Calithera Biosciences Inc. shed nearly half of its value and will cut about 30 jobs after a mid-stage clinical trial of its marquee drug failed in kidney cancer patients. The South San Francisco company (NASDAQ: CALA) said the job cuts represent 35% of its workforce. The bulk of the job losses would be among those prepping for a potential commercial launch of the drug, called telaglenastat or CB-839. The company's 444-person Phase II study found that advanced or m etastatic renal cell carcinoma… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 4, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news

Peninsula biotech Calithera cuts a third of jobs after kidney cancer trial flop
Calithera Biosciences Inc. shed nearly half of its value and will cut about 30 jobs after a mid-stage clinical trial of its marquee drug failed in kidney cancer patients. The South San Francisco company (NASDAQ: CALA) said the job cuts represent 35% of its workforce. The bulk of the job losses would be among those prepping for a potential commercial launch of the drug, called telaglenastat or CB-839. The company's 444-person Phase II study found that advanced or m etastatic renal cell carcinoma… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - January 4, 2021 Category: American Health Authors: Ron Leuty Source Type: news

Renal Cell Carcinoma Highlights From ESMO 2020 Renal Cell Carcinoma Highlights From ESMO 2020
Dr Robert Motzer reviews key studies on renal cell carcinoma presented at the 2020 ESMO Virtual Congress, including phase 3 trial results showing benefit from combination therapies in advanced RCC.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 8, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Immunotherapy Combo Treats Advanced Kidney Cancer
FRIDAY, Oct. 2, 2020 -- Nivolumab combined with cabozantinib is superior to sunitinib alone for the treatment of advanced clear cell renal cell carcinoma, according to a study presented at the annual meeting of the European Society for Medical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 2, 2020 Category: Pharmaceuticals Source Type: news

Renal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment
Draft Guidance for Industry: Renal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 1, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Nivo-Cabo Combo Joins Advanced RCC Treatment Ranks Nivo-Cabo Combo Joins Advanced RCC Treatment Ranks
The PD-1 inhibitor/TKI combination is the latest to show superior survival in comparison with sunitinib as first-line therapy for patients with metastatic renal cell carcinoma (RCC).Medscape Medical News (Source: Medscape Urology Headlines)
Source: Medscape Urology Headlines - September 21, 2020 Category: Urology & Nephrology Tags: Hematology-Oncology News Source Type: news

Study Supports Changing Classification of Renal Cell Carcinoma Study Supports Changing Classification of Renal Cell Carcinoma
The definition of stage 4 renal cell carcinoma should be expanded to include lymph node-positive stage 3 disease, according to a new study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 7, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Certain pesticides linked to kidney cancer in agricultural workers
New findings from the Agricultural Health Study suggest exposure to certain pesticides may increase risk of renal cell carcinoma. (read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - July 6, 2020 Category: Environmental Health Source Type: news

Liquid Biopsy Promising in Spotting Kidney Cancer Liquid Biopsy Promising in Spotting Kidney Cancer
An assay employing plasma and urine cell-free DNA methylomes is capable of classifying patients across all stages of renal-cell carcinoma, according to preliminary studies.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - July 2, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Good Survival Rates After Percutaneous Cryoablation for Early Renal Cell Carcinoma Good Survival Rates After Percutaneous Cryoablation for Early Renal Cell Carcinoma
Percutaneous cryoablation yields survival rates at least as good as those with nephrectomy in patients with stage 1 renal cell carcinoma, according to a prospective observational study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 11, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Oncotarget: Hyperprogression to immune blockade followed by a response with cabozantinib
(Impact Journals LLC) Volume 11, Issue 22 of @Oncotarget reported that more and more patients receive first-line treatment with immunotherapy combinations and not all patients respond in metastatic renal cell carcinoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 10, 2020 Category: Cancer & Oncology Source Type: news

Percutaneous Cryoablation Treats Early-Stage Kidney Cancer
TUESDAY, June 9, 2020 -- Percutaneous cryoablation (PCA) for stage I renal cell carcinoma (RCC) results in good outcomes, with a 10-year disease-specific survival of 94 percent, according to a study published online June 9 in Radiology. John... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 9, 2020 Category: Pharmaceuticals Source Type: news

Elizabeth Plimack, MD, MS, Discusses Subsequent Therapy in Advanced RCC
Elizabeth Plimack, MD, MS, discussed the role of subsequent immunotherapy when analyzing the primary endpoint of overall survival for axitinib and pembrolizumab over sunitinib in patients with advanced renal cell carcinoma evaluated in the updated analysis of KEYNOTE-426. (Source: CancerNetwork)
Source: CancerNetwork - June 9, 2020 Category: Cancer & Oncology Authors: Elizabeth R. Plimack, MD, MS Source Type: news

Eric Jonasch, MD, on Next Steps in MK-6482 in VHL Disease –Associated RCC
The MD Anderson Cancer Center expert discussed next steps for those with von Hippel-Lindau disease –associated renal cell carcinoma being treated with the HIF-2a Inhibitor. (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2020 Category: Cancer & Oncology Authors: Eric Jonasch, MD Source Type: news

Eric Jonasch, MD, Discusses Use of MK-6482 in VHL Disease –Associated Kidney Cancer
The HIF-2a Inhibitor, MK-6482, induced clinical responses among patients with von Hippel-Lindau disease –associated renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Eric Jonasch, MD Source Type: news

Final Data Analysis Supports Tivozanib as Superior Treatment for Patients With RCC
When compared with sorafenib, tivozanib showed improved progression-free survival, and a more manageable safety profile for patients with relapsed or refractory metastatic renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news

Savolitinib Induces Encouraging Efficacy, Safety in MET-Driven Papillary Renal Cell Carcinoma
A phase III study presented the 2020 ASCO Virtual Scientific Program showed encouraging efficacy data suggesting savolitinib could be used to treat patients with MET-driven papillary renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Novel targeted drug induced positive response for VHL-associated kidney cancer
(University of Texas M. D. Anderson Cancer Center) In an international trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with MK-6482, the small molecule inhibitor of hypoxia-inducible factor (HIF)-2a was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease (VHL)-associated renal cell carcinoma (RCC). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 28, 2020 Category: Cancer & Oncology Source Type: news

Tivozanib Induces Durable Response Among Patients with Advanced Renal Cell Carcinoma
The VEGF TKI induced durable responses and favorable tolerability in patients with relapsed/refractory RCC. (Source: CancerNetwork)
Source: CancerNetwork - May 20, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Mesothelioma Drug Combination Continues to Show Promise
Pharmaceutical giant Bristol Myers Squibb continues to tout its immunotherapy combination of Opdivo and Yervoy for first-line treatment of patients with pleural mesothelioma cancer. Bristol Myers Squibb recently announced that overall survival “significantly improved” when the combination was measured against standard chemotherapy in a randomized, phase III clinical trial of previously untreated mesothelioma patients. Its announcement was based on a pre-specific interim analysis conducted by the Data Monitoring Committee, a clinical study organization independent of Bristol Myers Squibb. The study is being cond...
Source: Asbestos and Mesothelioma News - May 4, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Phase III CheckMate-9ER Trial Meets Primary Endpoint in Advanced RCC Trial
The trial evaluated nivolumab in combination with cabozantinib compared to sunitinib in previously untreated advanced or metastatic renal cell carcinoma, meeting its primary endpoint of progression-free survival at final analysis. (Source: CancerNetwork)
Source: CancerNetwork - April 21, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Renal Cell Cancer
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - April 15, 2020 Category: General Medicine Source Type: news